vatalanib has been researched along with temozolomide in 3 studies
| Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) | Studies (temozolomide) | Trials (temozolomide) | Recent Studies (post-2010) (temozolomide) |
|---|---|---|---|---|---|
| 276 | 42 | 98 | 6,014 | 826 | 4,331 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brandes, AA; Gorlia, T; Hau, P; Kros, JM; Lacombe, D; Mirimanoff, RO; Stupp, R; Tosoni, A; van den Bent, MJ | 1 |
| Liu, JM; Tang, GS; Wang, Y; Yue, ZJ; Zhang, H; Zhang, YH | 1 |
| Batchelor, TT; Doyle, CL; Drappatz, J; Duda, DG; Eichler, AF; Gerstner, ER; Jain, RK; Plotkin, SR; Wen, PY; Xu, L | 1 |
2 trial(s) available for vatalanib and temozolomide
| Article | Year |
|---|---|
EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Phthalazines; Pyridines; Radiotherapy, Adjuvant; Temozolomide; Treatment Outcome | 2010 |
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Membrane Proteins; Middle Aged; Phthalazines; Polymorphism, Single Nucleotide; Pyridines; Radiotherapy; Receptor, TIE-2; Temozolomide; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
1 other study(ies) available for vatalanib and temozolomide
| Article | Year |
|---|---|
Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Models, Animal; Drug Delivery Systems; Glioma; Humans; Lactic Acid; Male; Neovascularization, Pathologic; Phthalazines; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyridines; Rats; Rats, Sprague-Dawley; Temozolomide; Treatment Outcome | 2010 |